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Abstract
Large  cell  neuroendocrine  carcinoma
(LCNEC) of the uterine cervix is a rare and
aggressive  malignancy  with  poor  prognosis
even in its early stage, despite multimodality
treatment strategy. Here, we report a case of a
woman with clinical polypoid stage IB LCNEC
of the cervix, which was detected in her 6-week
postpartum checkup. A literature review was
also conducted to evaluate current therapeutic
approaches and potential new strategies.
Introduction
Neuroendocrine  tumors  of  the  uterine
cervix are a group of uncommon neoplasms
characterized as highly aggressive and prone
to early metastasis. They are classified as typi-
cal carcinoid, atypical carcinoid, small cell car-
cinoma (SCC) and large cell neuroendocrine
carcinoma (LCNEC) based on mitotic activity,
nuclear atypia and geographic type of necro-
sis.1 In  contrast  to  SCC  whose  aggressive
behavior and resistance to therapy have been
well-established,  cervical  LCNEC  was  often
under-recognized and misdiagnosed as poorly
differentiated adeno- or squamous cell carci-
noma until 1997 when Gilks et al.2 reported 12
cervical LCNEC cases. Since then, nearly 70
cases have been reported from either a clinical
or pathological standpoint. However, prognosis
for this population remains bleak despite mul-
timodal  treatments,  and  the  majority  of
patients die within 2 to 3 years of diagnosis
(Table 1). Here, we report a case of early stage
LCNEC treated with surgery followed by adju-
vant therapy with cisplatin and etoposide and
review the literature on the effectiveness of
current treatment strategies and examine new
approaches that are being developed to treat
LCNEC.
Case Report
A 33-year-old Caucasian female (G4 P3-0-1-
3) arrived for her 6-week postpartum checkup,
and a speculum examination revealed a 1.2 cm
cervical  polyp.  A  liquid-based  Pap  specimen
showed abundant clusters of overlapping tumor
cells with scant cytoplasm, finely granular chro-
matin and conspicuous mitotic activity (Figure
1a). Upon reevaluation 4 weeks later, the polyp
was still present, and the patient underwent
polypectomy. An approximately 2¥2 cm polyp
was submitted for histopathological analysis.
The specimen consisted entirely of tumor, a
poorly  differentiated  carcinoma  with  a  solid
and trabecular architecture (Figure 1b). The
tumor cells were large, with a high nuclear-to-
cytoplasmic ratio, small nucleoli, finely granu-
lar chromatin and numerous mitotic figures,
including  atypical  mitoses  (Figure  1c).  On
immunohistochemical  staining,  the  tumor
showed diffuse positive immunoreactivity for
cytokeratin AE1/AE3 (Figure 1d) and neuroen-
docrine  markers,  including  chromogranin
(Figure 1e) and synaptophysin (Figure 1f) and
CD56.  Immunostain  for  S-100,  another  neu-
roendocrine  marker,  was  weakly  positive.  In
addition, the tumor cells were focally weakly
positive  for  P63,  a  marker  of  cervical  basal
cells, which is diffusely positive in squamous
cell carcinoma of the cervix but is negative or
only focally positive in cervical neuroendocrine
carcinomas.3 These morphologic and immuno-
histochemical  findings  are  consistent  with
LCNEC.  The  tumor  had  KRAS  mutation
(Gly12Asp), but no EGFR or BRAF mutations.
The tumor also had low levels of EGFR expres-
sion, and high levels of thymidylate synthase,
ERCC1, and RRM1 expression.
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Figure 1. Large cell neuroendocrine carcinoma of the cervix. a) Liquid-based Pap speci-
men showing clusters of tumor cells. Notice a mitotic figure in the bottom half of the
cluster (Pap stain, original magnification ¥400). b) Tumor with a solid and trabecular
architecture (hematoxylin and eosin, original magnification ¥100). c) Large tumor cells
with a high nuclear-to-cytoplasmic ratio, small nucleoli, finely granular chromatin and
numerous mitotic figures, including atypical mitoses (arrow) (hematoxylin and eosin,
original magnification ¥400). d) Tumor cells with diffuse and strong positive immunore-
activity for cytokeratin AE1/AE3 (immunostain for cytokeratin AE1/AE3, original mag-
nification ¥100). e) Positive immunostaining of the tumor for chromogranin (immunos-
tain for chromogranin, original magnification ¥200). f) Positive immunostaining of the
tumor for synaptophysin (immunostain for synaptophysin, original magnification ¥200).[Rare Tumors 2012; 4:e18] [page 59]
Radical hysterectomy with bilateral salpingo-
oophorectomy and bilateral pelvic and periaortic
lymph node dissection was performed, followed
by baseline PET/CT and brain MRI scans, show-
ing no evidence of regional or distant metasta-
sis.  The  clinical  picture  was  consistent  with
stage IB disease, as defined by the Federation of
Gynaecologists and Obstetricians (FIGO) stag-
ing system for carcinoma of the uterine cervix. 
Due to the aggressive morphology, adjuvant
therapy with intravenous cisplatin and etopo-
side was started. A total of five 21-day cycles
were given, with minimal toxicity consisting of
grade 1 peripheral neuropathy, which resolved
3 months after the last cycle of treatment. At
the 24-month follow-up, there was no evidence
of disease recurrence. 
Discussion
Knowledge on LCNEC of the uterine cervix
has gradually accumulated over the past two
decades, since a clear classification of cervical
neuroendocrine-differentiated  tumors  was
established  in  1997.  More  than  70  LCNEC
cases have been reported since then (Table 1).
Neuroendocrine  carcinomas  comprise  less
than  5%  of  all  cervical  cancers,  with  SCCs
being  the  most  common  and  LCNECs  being
rare.4 Patients with LCNEC often present in
the early stages with vaginal bleeding or are
diagnosed  during  regular  vaginal  check-ups.
They may also occasionally present with carci-
nomatous meningitis5 or mimic vaginitis.6 We
did not perform molecular studies for human
papillomavirus  (HPV)  on  this  tumor,  but
LCNECs of the cervix have been reported to be
associated with high-risk HPV types 16 and 18
and, to a lesser extent, types 31 and 33.7
Due to the rarity of cervical LCNEC, no con-
sensus has been reached on an optimal treat-
ment plan, and current multimodal strategies
that  combine  radical  hysterectomy  (with  or
without  bilateral  salpingo-oophorectomy),
chemotherapy and radiation are mainly adapt-
ed from treatments used for neuroendocrine
carcinomas of the lung.8 While the role of sur-
gical intervention remains controversial with
no sign of improving long-term survival so far,
chemotherapy has become the mainstream of
management, especially considering LCNEC’s
aggressive, early metastatic behavior.9 Among
various  chemotherapy  options,  the  combina-
tion of cisplatin and etoposide is most common
and was used for our patient as well. Three
other  commonly  used  combinations  include
vincristine,  doxorubicin  and  cyclophospho-
mide, carboplatin plus paclitaxel and occasion-
ally epirubicin, topotecan plus thalidomide. A
recent systematic review of published cases10
has also indicated that, while the addition of
chemotherapy at any point of initial treatment
will  offer  survival  benefits,  platinum  with
(P=0.0027) or without etoposide (P=0.0034)
in particular is associated with statistically sig-
nificant improvement in survival compared to
chemo-regimens without these agents.
However, regardless of great efforts invest-
ed, the majority of LCNEC patients do not sur-
vive more than two years after being diagnosed
Case Report
Table 1. A summary of 78 cases reported of large cell neuroendocrine cervical carcinoma
(current case included).
First author Age Stage Treatment Outcome
(No. of cases) (No. of cases) (No. of cases)
Gilks (12)  36-38 IA2 RH(1) 36+mo (1)
RH with Chemo (1) NA(1)
21-36 IB RH (1) 24 mo(1)
RH+ Chemo (6) 8-12mo(3), 6+-36+mo (3)
RH + Chemo +RT(2) 18-24 mo(2)
62 IIA RH 6mo
Tsou (1) 35 IIB Chemo+RT 18mo (1)
Yun (1) 31 IA1 RH 10+mo (1)
Krivak (2)  25 IB RH; chemo for met 35mo (1)
36 IIA RH+ Chemo 33mo (1)
Cui (1) 35 NA Neoadjuvant Chemo+ RH NA
Rhemtula (5) 55 IIB None (1) 1+mo (1)
(South Africa) 75 IIIB RT (1) 3mo (1)
51-65 IVB None (1) 0.25mo (1)
RT (1) 1mo (1)
42 NA None (1) NA (1)
Grayson (12) 42-72 NA NA NA 
Wen (1)  57 IIB TAHBSO+ RT  41mo (1)
Dikmen (1) 45 IIB TAHBSO+ RT+ Chemo NA
Sato (6) 27-51 IB TAHBSO+RT+ Chemo(5) 12+-151+mo (2)
16-19mo(3)
42 IIA TAHBSO+RT+ Chemo(1) 6mo (1)
Kumar (1) 39 IV NA NA
Baykal (1) 38 IB TAHBSO+ Chemo+ RCT 21+mo (1)
Tangjitgamol (6) NA I NA (5) NA (6)
II NA (1)
Kawauchi (1) 40 IB TAHBSO 9mo+ (1)
Cetiner (1) 47 IIB TAHBSO+ RT 6mo+ (1)
Wang (4) 42+/- IA2 RT+ Chemo (1) NA
11.3 IB1 RT+ Chemo (3)
Ko (1) 45 IB RH+RT+ Chemo  24mo+ (1)
Tangjitgamol (1) 42 III Chemo 44mo (1)
McCluggage (3) 72 I RT+ Chemo NA (1)
32 IIB TAHBSO+RT+ Chemo 17mo (1)
48 IVB RT+ Chemo NA (1)
Saavedra (2) 25-42 IB RT+ Chemo (2) 36+-60+mo (2)
Powell (1)  31 IIIB TAHBSO+RT+ Chemo NA
Kajiwara (2) 55 IIA NA 12mo (1)
37 IIIB NA 21mo (1)
Li (1) 30 IIB RT+ Chemo 23mo+ (1)
Wang (7) 37 IA2 RH+ Chemo (1) 17.2mo (1)
28-48 IB1 RH (1) 114.3+mo (1)
RH+ Chemo (2) 3-17.2mo (2)
RH+ Chemo+ RT(1) 39mo (1)
41-62 IB2 RH (1) 7mo (1)
BSH+ Chemo+ RT(1)  11.8mo (1)
Markopoulos (1) 60 NA RH+ Chemo+ RT 18mo (1)
Brown (1) 40  IVB Chemo NA
Embry (1)  24 IB2 RH+ Chemo+ RT  47mo+ 
Yoseph (1) 33 IB TAHBSO+Chemo 24 months
(current study)
RT, radiotherapy; RCH, radio-chemotherapy; Chemo, chemotherapy; RH, radical hysterectomy; BSO, bilateral salpingo-oophorectomy; TAHBSO,
total hysterectomy with bilateral salpingo-oophorectomy; NA, not available; in outcome, + indicates being alive/censored, otherwise died.[page 60] [Rare Tumors 2012; 4:e18]
(Table 1). Accordingly, novel treatment strate-
gies have been proposed that require further
evaluation. Tangjitgamol et al.11 measured the
prevalence of estrogen receptor and/or proges-
terone receptor among neuroendocrine tumors
to evaluate the feasibility of applying hormon-
al treatment to cervical LCNEC patients, but
unfortunately  only  a  very  small  portion  of
recruited  patients  (3  out  of  24)  expressed
these  hormonal  receptors.  Another  strategy
was  proposed  by  Kajiwara  et  al.12 using  the
somatostatin  type  2A  (SSTR2A)  analog,
octreotide,  to  treat  neuroendocrine  tumors,
given that 3 out of 7 cases (2 out of 5 SCC and
1 out of 2 LCNEC) expressed SSTR2A recep-
tors; however, this strategy has not been tested
yet in a larger study. 
In conclusion, chemotherapy is associated
with improved survival and should be consid-
ered in resected cases. 
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